Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101776 | 1.00 | MEN1 (0.40) | MEN1KMT2AL3MBTL1PPARGPPARD | |
| SCHEMBL10102188 | 0.88 | SMN1; SMN2 (0.39) | MEN1KMT2AL3MBTL1ACHES1PR1 | |
| SCHEMBL10102195 | 0.88 | SMN1; SMN2 (0.39) | MEN1KMT2AL3MBTL1ACHES1PR1 | |
| SCHEMBL15251330 | 0.77 | HTT (0.39) | MEN1KMT2AL3MBTL1S1PR1 | |
| SCHEMBL15251319 | 0.77 | HTT (0.39) | MEN1KMT2AL3MBTL1S1PR1 | |
| SCHEMBL10101728 | 0.74 | MAPT (0.39) | MEN1KMT2AL3MBTL1PPARGPPARD | |
| SCHEMBL10101726 | 0.73 | S1PR1 (0.48) | L3MBTL1PPARGPPARDPPARAS1PR1 | |
| SCHEMBL10102194 | 0.72 | MEN1 (0.39) | MEN1KMT2AESR2ACHECYP2D6 | |
| SCHEMBL10102187 | 0.72 | MEN1 (0.39) | MEN1KMT2AESR2ACHECYP2D6 | |
| SCHEMBL10102192 | 0.72 | MEN1 (0.39) | MEN1KMT2AESR2ACHECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | MEN1 3782/4885KMT2A 4832/4885L3MBTL1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.